Risk Factors for Incident Diabetic Polyneuropathy in a Cohort With Screen-Detected Type 2 Diabetes Followed for 13 Years: ADDITION-Denmark
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To study incident diabetic polyneuropathy (DPN) prospectively during the first 13 years after a screening-based diagnosis of type 2 diabetes and determine the associated risk factors for the development of DPN. RESEARCH DESIGN AND METHODS: We assessed DPN longitudinally in the Danish arm of the Anglo-Danish-Dutch study of Intensive Treatment of Diabetes in Primary Care (ADDITION) using the Michigan Neuropathy Screening Instrument questionnaire (MNSIQ), defining DPN with scores ≥4. Risk factors present at the diabetes diagnosis associated with the risk of incident DPN were estimated using Cox proportional hazard models adjusted for trial randomization group, sex, and age. RESULTS: Of the total cohort of 1,533 people, 1,445 completed the MNSIQ at baseline and 189 (13.1%) had DPN at baseline. The remaining 1,256 without DPN entered this study (median age 60.8 years [interquartile range 55.6; 65.6], 59% of whom were men). The cumulative incidence of DPN was 10% during 13 years of diabetes. Age (hazard ratio [HR] 1.03 [95% CI 1.00; 1.07]) (unit = 1 year), weight (HR 1.09 [95% CI 1.03; 1.16]) (unit = 5 kg), waist circumference (HR 1.14 [95% CI 1.05; 1.24]) (unit = 5 cm), BMI (HR 1.14 [95% CI 1.06; 1.23]) (unit = 2 kg/m2), log2 methylglyoxal (HR 1.45 [95% CI 1.12; 1.89]) (unit = doubling), HDL cholesterol (HR 0.82 [95% CI 0.69; 0.99]) (unit = 0.25 mmol/L), and LDL cholesterol (HR 0.92 [95% CI 0.86; 0.98]) (unit = 0.25 mmol/L) at baseline were significantly associated with the risk of incident DPN. CONCLUSIONS: This study provides further epidemiological evidence for obesity as a risk factor for DPN. Moreover, low HDL cholesterol levels and higher levels of methylglyoxal, a marker of dicarbonyl stress, are identified as risk factors for the development of DPN.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Neuropathic pain can lead to interference with daily activities, disability, psychosocial impairment, and reduced health-related QoL.547,552,562,563”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [547]
In the citing paper
“The earliest affected nerve fibers are usually the small myelinated and unmyelinated fibers; thus, the most common early symptoms are pain and dysesthesias (unpleasant sensations of burning).547,554,555”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [547]
In the citing paper
“Characteristically, the pain is burning, lancinating, tingling, or shooting (electric shock-like), with paresthesia, occurring in varying combinations, and is typically worse at night547”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [547]
In the citing paper
“However, the presence of atypical features including motor deficits greater than sensory, asymmetry of symptoms and signs, and rapid progression warrant a timely referral.547”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [547]
In the citing paper
“A combination of typical symptomatology and symmetrical distal sensory loss, or typical signs in the absence of symptoms, in a person with DM is highly suggestive of DPN and may not require additional evaluations or referral.547,565–567”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [547]
37 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690
Diabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602 · cited 2×
“DPN increases the risk of chronic pain, falls, foot ulcers, and amputations; it also negatively affects the quality of life (3).”
BackgroundResultSelf-citationDyck, P. J., Kratz, K. M., Karnes, J. L., Litchy, W. J., Klein, R., Pach, J. M., Wilson, D. M., O'Brien, P. C., & Melton, L. J. (1993) · Neurology · doi:10.1212/wnl.43.4.817 · Cited by 1,482 · cited 1×
“Of these, diabetic polyneuropathy (DPN) is the most common complication (2).”
BackgroundVascular risk factors and diabetic neuropathy
Tesfaye, S., Chaturvedi, N., Eaton, S. E. M., Ward, J. D., Manes, C., Ionescu-Tirgoviste, C., Witte, D. R., & Fuller, J. H. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa032782 · Cited by 1,323
Self-citationFeldman, E. L., Stevens, M. J., Thomas, P. K., Brown, M. B., Canal, N., & Greene, D. A. (1994) · Diabetes Care · doi:10.2337/diacare.17.11.1281 · Cited by 1,293
Self-citationDiabetic neuropathy: clinical manifestations and current treatments
Callaghan, B. C., Cheng, H. T., Stables, C. L., Smith, A. L., & Feldman, E. L. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70065-0 · Cited by 1,211
Self-citationThe global burden of diabetes and its complications: an emerging pandemic
Susan van, D., Beulens, J. W. J., Yvonne T. van der, S., Grobbee, D. E., & Nealb, B. (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000368191.86614.5a · Cited by 874 · cited 2×
“patients with diabetes over the course of their lives (1,4,5).”
BackgroundAdvances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy
Tesfaye, S., & Selvarajah, D. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2239 · Cited by 615 · cited 1×
“Other metabolic syndrome components such as obesity, hypertension, low HDL cholesterol, and hypertriglyceridemia are among the potential additional risk factors for the development of DPN (6,8,10).”
Background
Cited by
Feldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., Bril, V., Russell, J. W., & Viswanathan, V. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0092-1 · Cited by 1,697
Self-citationSchalkwijk, C. G., & Stehouwer, C. D. A. (2020) · Physiological Reviews · doi:10.1152/physrev.00001.2019 · Cited by 622
Selvarajah, D., Kar, D., Khunti, K., Davies, M. J., Scott, A. R., Walker, J., & Tesfaye, S. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30081-6 · Cited by 556
Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
Sloan, G., Selvarajah, D., & Tesfaye, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00496-z · Cited by 534
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Elafros, M. A., Andersen, H., Bennett, D. L., Savelieff, M. G., Viswanathan, V., Callaghan, B. C., & Feldman, E. L. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00188-0 · Cited by 387
Self-citationChallenges of neuropathic pain: focus on diabetic neuropathy
Rosenberger, D. C., Blechschmidt, V., Timmerman, H., Wolff, A., & Treede, R.-D. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02145-7 · Cited by 325
New perspectives in diabetic neuropathy
Eid, S. A., Rumora, A. E., Beirowski, B., Bennett, D. L., Hur, J., Savelieff, M. G., & Feldman, E. L. (2023) · Neuron · doi:10.1016/j.neuron.2023.05.003 · Cited by 257
Self-citationPeripheral Neuropathy in Diabetes Mellitus: Pathogenetic Mechanisms and Diagnostic Options
Galiero, R., Caturano, A., Vetrano, E., Beccia, D., Brin, C., Alfano, M., Di Salvo, J., Epifani, R., Piacevole, A., Tagliaferri, G., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043554 · Cited by 225
“In contrast, DPN may already be present at the time of diagnosis in individuals with T2DM, and in this case, the prevalence increases together with the increasing age of the patient and the time duration of the diabetes [2,7,8].”
Background12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gibbons, C. H., Giurini, J. M., Hilliard, M. E., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s012 · Cited by 207
Emerging Biomarkers, Tools, and Treatments for Diabetic Polyneuropathy
Bönhof, G. J., Herder, C., Strom, A., Papanas, N., Roden, M., & Ziegler, D. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00107 · Cited by 221
Geng, T., Zhu, K., Lu, Q., Wan, Z., Chen, X., Liu, L., Pan, A., & Liu, G. (2023) · PLOS Medicine · doi:10.1371/journal.pmed.1004135 · Cited by 205
Advances in Screening, Early Diagnosis and Accurate Staging of Diabetic Neuropathy
Carmichael, J., Fadavi, H., Ishibashi, F., Shore, A. C., & Tavakoli, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.671257 · Cited by 176
“In cohorts of patients with T2DM, several metabolic syndromes such as hypertension, abdominal obesity, lower high-density lipoprotein (HDL) levels and hypertriglyceridemia have been consistently associated with DPN development (23), with additional independent risk factors including alcohol abuse and increased height…”
BackgroundPainful and Painless Diabetic Neuropathies: What Is the Difference?
Shillo, P., Sloan, G., Greig, M., Hunt, L., Selvarajah, D., Elliott, J., Gandhi, R., Wilkinson, I. D., & Tesfaye, S. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1150-5 · Cited by 183
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Callaghan, B. C., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s012 · Cited by 176
Self-citationDiabetic neuropathy: what does the future hold?
Callaghan, B. C., Gallagher, G., Fridman, V., & Feldman, E. L. (2020) · Diabetologia · doi:10.1007/s00125-020-05085-9 · Cited by 158
“The studies conducted in Denmark, the Netherlands and Germany also highlighted obesity as a neuropathy risk factor, replicating the study findings in China and the USA.”
BackgroundSelf-citation12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gibbons, C. H., Giurini, J. M., Hilliard, M. E., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s012 · Cited by 169
Diabetic neuropathy and neuropathic pain: a (con)fusion of pathogenic mechanisms?
Calcutt, N. A. (2020) · Pain · doi:10.1097/j.pain.0000000000001922 · Cited by 159
“Recent studies have confirmed the pronociceptive properties of methylglyoxal in humans,(92) and elevated plasmamethylglyoxal has been identified as a risk factor for neuropathy in patients with type 2 diabetes.(13) Approaches in reducing methylglyoxal levels or blocking downstream consequences are in development.”
BackgroundInflammatory Mechanisms in the Pathophysiology of Diabetic Peripheral Neuropathy (DN)—New Aspects
Baum, P., Toyka, K. V., Blüher, M., Kosacka, J., & Nowicki, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910835 · Cited by 209
The global and regional burden of diabetic peripheral neuropathy
Savelieff, M. G., Elafros, M. A., Viswanathan, V., Jensen, T. S., Bennett, D., & Feldman, E. L. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01041-y · Cited by 195
“Importantly, most studies to date have been cross-sectional and, therefore, have failed to provide information on global DPN incidence 174 , as well as the natural history of the disease 18 .”
Self-citationYang, H., Sloan, G., Ye, Y., Wang, S., Duan, B., Tesfaye, S., & Gao, L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00929 · Cited by 151
Vascular complications of diabetes: A narrative review
Lu, Y., Wang, W., Liu, J., Xie, M., Liu, Q., & Li, S. (2023) · Medicine · doi:10.1097/md.0000000000035285 · Cited by 215
“[57,58] Genetic studies have identified several genes linked to diabetic neuropathy; however, more verification in larger populations, especially with cohort studies, is needed.”
Gylfadottir, S. S., Christensen, D. H., Nicolaisen, S. K., Andersen, H., Callaghan, B. C., Itani, M., Khan, K. S., Kristensen, A. G., Nielsen, J. S., Sindrup, S. H., et al. (2020) · Pain · doi:10.1097/j.pain.0000000000001744 · Cited by 151
“(18%) and painful DPN (10%) found in this study are similar to the prevalence reported in 2 survey studies using the MNSIq for the diagnosis of DPN and the MNSIq in combination with brief pain inventory (BPI) to diagnose painful DPN.(2,43) In the ADDITION Denmark cohort study consisting of 1445 screenings-detected typ…”
MethodResultSelf-citationEarly Detection of Diabetic Peripheral Neuropathy: A Focus on Small Nerve Fibres
Burgess, J., Frank, B., Marshall, A. G., Khalil, R. S., Ponirakis, G., Petropoulos, I. N., Cuthbertson, D. J., Malik, R. A., & Alam, U. (2021) · Diagnostics · doi:10.3390/diagnostics11020165 · Cited by 179
“ticipants with and without DPN [86], however the corneal nerve analysis was undertaken”
BackgroundMethodMethylglyoxal Metabolism and Aging-Related Disease: Moving from Correlation toward Causation
Kold-Christensen, R., & Johannsen, M. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.10.003 · Cited by 146
TRPA1 Antagonists for Pain Relief
Koivisto, A., Jalava, N., Bratty, R., & Pertovaara, A. (2018) · Pharmaceuticals · doi:10.3390/ph11040117 · Cited by 123
“These experimental findings are in agreement with clinical observations demonstrating that methylglyoxal is increased both in type 1 and type 2 diabetes [54] and that an increased level of methylglyoxal is associated with the development of PDN symptoms [55,56].”
ResultCentral Obesity is Associated With Neuropathy in the Severely Obese
Callaghan, B. C., Reynolds, E., Banerjee, M., Chant, E., Villegas-Umana, E., & Feldman, E. L. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.03.025 · Cited by 115
Self-citationChristensen, D. H., Knudsen, S. T., Gylfadottir, S. S., Christensen, L. B., Nielsen, J. S., Beck-Nielsen, H., Sørensen, H. T., Andersen, H., Callaghan, B. C., Feldman, E. L., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2277 · Cited by 106
“Compared with previous studies of obesity (6,8,9,17,30), we additionally found that central fat distribution is associated with DPN independent of BMI.”
BackgroundResultInfluentialSelf-citationFerdousi, M., Kalteniece, A., Azmi, S., Petropoulos, I. N., Ponirakis, G., Alam, U., Asghar, O., Marshall, A. G., Fullwood, C., Jeziorska, M., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1482 · Cited by 110
“Furthermore, high BMI, hypertension, cholesterol, and triglycerides levels are associated with incident DPN in type 1 diabetes (11), and age, BMI, waist circumference, LDL cholesterol, and HDL cholesterol are associated with incident DPN in type 2 diabetes (12).”
BackgroundHanssen, N. M. J., Westerink, J., Scheijen, J. L. J. M., van der Graaf, Y., Stehouwer, C. D. A., Schalkwijk, C. G., SMART Study Group, Algra, A., van der Graaf, Y., Grobbee, R. D. E., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0159 · Cited by 103
Andersen, S. T., Witte, D. R., Fleischer, J., Andersen, H., Lauritzen, T., Jørgensen, M. E., Jensen, T. S., Pop-Busui, R., & Charles, M. (2018) · Diabetes Care · doi:10.2337/dc18-1411 · Cited by 99
Self-citationSchlesinger, S., Herder, C., Kannenberg, J. M., Huth, C., Carstensen-Kirberg, M., Rathmann, W., Bönhof, G. J., Koenig, W., Heier, M., Peters, A., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1842 · Cited by 93
“Only one recent prospective study reported a positive association between obesity and increased risk of diabetic polyneuropathy (7,8).”
BackgroundInfluentialDiabetic Neuropathy: Pathophysiology Review
Strand, N. H., Anderson, M. A., Attanti, S., Gill, B., Wie, C. S., Dawodu, A., Pagan-Rosado, R. D., Harbell, M. W., & Maloney, J. A. (2024) · Current Pain and Headache Reports · doi:10.1007/s11916-024-01243-5 · Cited by 110
Rumora, A. E., LoGrasso, G., Hayes, J. M., Mendelson, F. E., Tabbey, M. A., Haidar, J. A., Lentz, S. I., & Feldman, E. L. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.3173-18.2019 · Cited by 91
“…drivers of neuropathy in four human clinical studies: a 4000 subject Chinese cohort (Callaghan et al., 2018), a 1445 subject Danish cohort (Andersen et al., 2018), and two separate American cohorts including 102 subjects with a mean age of 52 years (Callaghan et al., 2016b) and 2383…”
BackgroundSelf-citationSpectrum of Diabetic Neuropathy: New Insights in Diagnosis and Treatment
Dillon, B. R., Ang, L. P., & Pop‐Busui, R. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-033114 · Cited by 105
O’Brien, P. D., Guo, K., Eid, S., Rumora, A. E., Hinder, L. M., Hayes, J. M., Mendelson, F. E., Hur, J., & Feldman, E. L. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.042101 · Cited by 89
“We have reported that dietary obesity coupled with impaired glucose tolerance are the primary metabolic factors linked to PN in four distinct clinical cohorts (Andersen et al., 2018; Callaghan et al., 2018, 2016a,b).”
BackgroundSelf-citationLipids and peripheral neuropathy
Iqbal, Z., Bashir, B., Ferdousi, M., Kalteniece, A., Alam, U., Malik, R. A., & Soran, H. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000770 · Cited by 80
“[43] T2DM Age, BMI, HDL-C, associated with”
Aktaş, G. (2024) · Biomolecules and Biomedicine · doi:10.17305/bb.2024.10426 · Cited by 78
Jende, J. M. E., Groener, J. B., Rother, C., Κender, Ζ., Hahn, A., Hilgenfeld, T., Juerchott, A., Preisner, F., Heiland, S., Kopf, S., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.4798 · Cited by 80
Self-citationA Comprehensive Review of Neuronal Changes in Diabetics
Luna, R., Manjunatha, R. T., Bollu, B., Jhaveri, S., Avanthika, C., Reddy, N., Saha, T., & Gandhi, F. R. (2021) · Cureus · doi:10.7759/cureus.19142 · Cited by 93
“Moreover, age, height, obesity, diastolic blood pressure, smoking status, chronic kidney disease, vascular disease, low HDL cholesterol level, high triglyceride, and glycosylated hemoglobin (HbA1c) levels are associated with a higher risk of neurologic complications in patients with DM especially polyneuropathy [31-34…”
BackgroundThe emerging role of dyslipidemia in diabetic microvascular complications
Savelieff, M. G., Callaghan, B. C., & Feldman, E. L. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000533 · Cited by 74
Self-citationEarly microvascular complications in type 1 and type 2 diabetes: recent developments and updates
Tommerdahl, K. L., Shapiro, A. L. B., Nehus, E. J., & Bjornstad, P. (2021) · Pediatric Nephrology · doi:10.1007/s00467-021-05050-7 · Cited by 86
“Additionally, peripheral neuropathy is closely linked with obesity [90, 94] and the milieu of the metabolic syndrome [95], including hypertension and dyslipidemia in young people with T1D [83] and with T2D [83, 96].”
BackgroundKatsiki, N., Anagnostis, P. G., Kotsa, K., Goulis, D. G., & Mikhailidis, D. P. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190708192134 · Cited by 73
Activation of the integrated stress response in nociceptors drives methylglyoxal-induced pain
Barragán-Iglesias, P., Kuhn, J., Vidal-Cantú, G. C., Salinas-Abarca, A. B., Granados-Soto, V., Dussor, G. O., Campbell, Z. T., & Price, T. J. (2019) · Pain · doi:10.1097/j.pain.0000000000001387 · Cited by 67
“levels can rise toexceptionally high levels, theseconcentrationsare30 to 1003 higher than those observed in diabetic neuropathic pain patients.(1,5) The first question we examine is if MGO produces pain at”
BackgroundPerkins, B. A., Lovblom, L. E., Lewis, E. J. H., Bril, V., Ferdousi, M., Orszag, A., Edwards, K. P., Pritchard, N., Russell, A. W., Dehghani, C., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0476 · Cited by 64
The Treatment of Painful Diabetic Neuropathy
SLOAN, G. P., Alam, U., Selvarajah, D., & Tesfaye, S. H. (2021) · Current Diabetes Reviews · doi:10.2174/1573399817666210707112413 · Cited by 71
Plasma lipid metabolites associate with diabetic polyneuropathy in a cohort with type 2 diabetes
Rumora, A. E., Guo, K., Alakwaa, F., Andersen, S. T., Reynolds, E. L., Jørgensen, M. E., Witte, D. R., Tankişi, H., Charles, M., Savelieff, M. G., et al. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51367 · Cited by 62
“In the Danish arm of the Anglo-Danish-Dutch study of Intensive Treatment of Diabetes in Primary Care (ADDITION), we identified waist circumference and low plasma HDL cholesterol, a MetS dyslipidemia component, as T2D DPN risk factors.(7) Alongside these MetS components, elevated levels of methylglyoxal, an oxidative s…”
BackgroundMethodResultInfluentialSelf-citationMethylglyoxal causes pain and hyperalgesia in human through C-fiber activation
Düll, M. M., Riegel, K., Tappenbeck, J., Ries, V., Strupf, M., Fleming, T. H., Sauer, S. K., & Namer, B. (2019) · Pain · doi:10.1097/j.pain.0000000000001644 · Cited by 61
Self-citationJeyam, A., McGurnaghan, S. J., Blackbourn, L. A. K., McKnight, J. M., Green, F., Collier, A., McKeigue, P. M., & Colhoun, H. M. (2020) · Diabetes Care · doi:10.2337/dc19-1582 · Cited by 59
“We defined symptomatic DPN based on the MNSIQ (17), using the validated threshold of a MNSIQ score of 4 or more (21) as evidence of the presence of symptomatic DPN; this criterion was also used in a recent study to define DPN (22).”
MethodElliott, D., SLOAN, G. P., Stevens, L. K., Selvarajah, D., Cruccu, G., Gandhi, R. A., Kempler, P., Fuller, J., Chaturvedi, N., Tesfaye, S. H., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-06025-z · Cited by 70
“The risk factors for DPN have been extensively studied in high-quality prospective studies [10, 11].”
BackgroundGylfadottir, S. S., Itani, M., Krøigård, T., Kristensen, A. G., Christensen, D. H., Nicolaisen, S. K., Karlsson, P., Callaghan, B. C., Bennett, D., Andersen, H., et al. (2020) · European Journal of Neurology · doi:10.1111/ene.14469 · Cited by 60
Self-citationAleidan, F. A. S., Ahmed, B. A., Alotaibi, F., Aleesa, D. H., Al-Hefdhi, N., Badri, M., & Gader, A. G. A. (2020) · International Journal of General Medicine · doi:10.2147/ijgm.s273807 · Cited by 56
The conundrum of diabetic neuropathies—Past, present, and future
Ang, L. P., Mizokami‐Stout, K., Eid, S., Elafros, M. A., Callaghan, B. C., Feldman, E. L., & Pop‐Busui, R. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108334 · Cited by 66
Self-citationPop‐Busui, R., Backlund, J. C., Bebu, I., Braffett, B. H., Lorenzi, G., White, N. H., Lachin, J. M., Soliman, E. Z., & DCCT/EDIC Research Group (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13635 · Cited by 52
Borbjerg, M. K., Wegeberg, A., Nikontovic, A., Mørch, C. D., Arendt‐Nielsen, L., Ejskjær, N., Brock, C., Vestergaard, P., & Røikjer, J. (2025) · Diabetes Care · doi:10.2337/dc24-2287 · Cited by 52
Herder, C., Roden, M., & Ziegler, D. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.02.007 · Cited by 54
Oh, T. J., Lee, J.-E., Choi, S. H., & Jang, H. C. (2019) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes.2019.28.2.112 · Cited by 59
Pathak, R., Sachan, N., & Chandra, P. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113025 · Cited by 62
Cardiometabolic risk factors as determinants of peripheral nerve function: the Maastricht Study
van der Velde, J. H. P. M., Koster, A., Strotmeyer, E. S., Mess, W. H., Hilkman, D. M. W., Reulen, J. P. H., Stehouwer, C. D. A., Henry, R. M. A., Schram, M. T., Kallen, C., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05194-5 · Cited by 51
Recent Advances in Biomarkers and Regenerative Medicine for Diabetic Neuropathy
Fujita, Y., Murakami, T., & Nakamura, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052301 · Cited by 50
“[20] reported a significant association, suggesting that higher levels of methylglyoxal are identified as risk factors for the development of diabetic neuropathy Thus, there are discrepancies in the results depending on the length of the survey period, and a detailed examination is awaited.”
BackgroundElzinga, S. E., Savelieff, M. G., O’Brien, P. D., Mendelson, F. E., Hayes, J. M., & Feldman, E. L. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.048909 · Cited by 55
“These mouse data parallel our clinical experience of sex not being a risk factor for incident PN in adult patients with diabetes (Andersen et al., 2018) or obese patients (Callaghan et al., 2020b, 2016b; Reynolds et al., 2020).”
Self-citationLian, X., Qi, J., Yuan, M., Li, X., Wang, M., Li, G., Yang, T., & Zhong, J. (2023) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-023-02232-1 · Cited by 48
“It was shown that LDL-C might cause nerve damage [32, 38, 39] while HDL-C protects against it [40].”
BackgroundAndersen, S. T., Grosen, K., Tankişi, H., Charles, M., Andersen, N. T., Andersen, H., Petropoulos, I. N., Malik, R. A., Jensen, T. S., & Karlsson, P. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.09.016 · Cited by 46
Self-citationSerum lipidomic determinants of human diabetic neuropathy in type 2 diabetes
Afshinnia, F., Reynolds, E. L., Rajendiran, T. M., Soni, T., Byun, J., Savelieff, M. G., Looker, H. C., Nelson, R. G., Michailidis, G., Callaghan, B. C., et al. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51639 · Cited by 40
“In the Danish ADDITION type 2 diabetes cohort, peripheral neuropathy is associated with decreased high-density lipoprotein cholesterol.(3) This relationship was also present in older populations, in the Health, Aging and Body Composition study,(9) and in youths, in the SEARCH for Diabetes in Youth study.”
BackgroundSelf-citationZiegler, D., Strom, A., Straßburger, K., Knebel, B., Bönhof, G. J., Kotzka, J., Szendroedi, J., Roden, M., & for the German Diabetes Study group (2020) · Diabetologia · doi:10.1007/s00125-020-05310-5 · Cited by 40
“Furthermore, the Anglo-Danish-Dutch Study of Intensive Treatment in People With Screen-Detected Diabetes in Primary Care (ADDITION)-Denmark study showed that hypertriacylglycerolaemia was associated with prevalent CAN [6], while low HDL-cholesterol levels were predictors of incident polyneuropathy over 13 years [7].”
BackgroundProgression and regression of nerve fibre pathology and dysfunction early in diabetes over 5 years
Ziegler, D., Bönhof, G. J., Strom, A., Straßburger, K., Karusheva, Y., Szendroedi, J., & Roden, M. (2021) · Brain · doi:10.1093/brain/awab330 · Cited by 45
Risk-Factor Trajectories Preceding Diabetic Polyneuropathy: ADDITION-Denmark
Andersen, S. T., Witte, D. R., Andersen, H., Bjerg, L., Bruun, N. H., Jørgensen, M. E., Finnerup, N. B., Lauritzen, T., Jensen, T. S., Tankişi, H., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0392 · Cited by 38
“Likewise, no difference was seen in our prospective study of DPN (17).”
BackgroundResultInfluentialSelf-citationDietary weight loss in people with severe obesity stabilizes neuropathy and improves symptomatology
Callaghan, B. C., Reynolds, E. L., Banerjee, M., Akinci, G., Chant, E., Villegas‐Umana, E., Rothberg, A. E., Burant, C. F., & Feldman, E. L. (2021) · Obesity · doi:10.1002/oby.23246 · Cited by 37
Self-citationDicarbonyl Stress in Diabetic Vascular Disease
Stratmann, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116186 · Cited by 44
“For a long time, it was estimated that T2DM is associated with a more pronounced atherosclerotic risk, but it has become evident that both T1DM and T2DM share a comparable risk for the development of the disease.”
BackgroundInfluentialGriggs, R. B., Santos, D. F., Laird, D. E., Doolen, S., Donahue, R. R., Wessel, C. R., Fu, W., Sinha, G. P., Wang, P., Zhou, J., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.02.019 · Cited by 37
Self-citationMather, K. J., Bebu, I., Baker, C., Cohen, R. M., Crandall, J. P., DeSouza, C., Green, J. B., Kirkman, M. S., Krause-Steinrauf, H., Larkin, M., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108235 · Cited by 34
“0% after approximately six years followup and 15% after thirteen years of follow-up [34].”
BackgroundA High-Fat Diet Disrupts Nerve Lipids and Mitochondrial Function in Murine Models of Neuropathy
Rumora, A. E., Guo, K., Hinder, L. M., O’Brien, P. D., Hayes, J. M., Hur, J., & Feldman, E. L. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.921942 · Cited by 35
Self-citationLipid metabolism alterations in peripheral neuropathies
Silva, A., Prior, R. C., D’Antonio, M., Swinnen, J. V., & Bosch, L. V. D. (2025) · Neuron · doi:10.1016/j.neuron.2025.04.006 · Cited by 35
Diet and Obesity-Induced Methylglyoxal Production and Links to Metabolic Disease
Hernandez-Castillo, C., & Shuck, S. C. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.1c00221 · Cited by 37
Määttä, L. L., Charles, M., Witte, D. R., Bjerg, L., Jørgensen, M. E., Jensen, T. S., & Andersen, S. T. (2019) · Diabetes Care · doi:10.2337/dc19-0869 · Cited by 31
“focused on studying the prevalence and incidence of DPN and the risk factors associated with this condition (3,4), little is known about the natural history of DPN, including development of both painful and painless symptoms (5,6).”
BackgroundSelf-citationJende, J. M. E., Κender, Ζ., Rother, C., Alvarez-Ramos, L., Groener, J. B., Pham, M., Morgenstern, J., Oikonomou, D., Hahn, A., Juerchott, A., et al. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.570744 · Cited by 32
“Although all of the risk factors correlated with DRG volume or SI have been shown to be risk factors for the development of DPN in longitudinal clinical studies, (Jaiswal et al., 2017; Andersen et al., 2018) our study does not allow for definite conclusions on a causal relation between serological risk factors and DRG…”
BackgroundResultSelf-citationStatin Therapy and Risk of Polyneuropathy in Type 2 Diabetes: A Danish Cohort Study
Kristensen, F. P., Christensen, D. H., Callaghan, B. C., Kahlert, J. A., Knudsen, S. T., Sindrup, S. H., Feldman, E. L., Østergaard, L., Andersen, H., Jensen, T. S., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1004 · Cited by 37
Self-citationDiabetic neuropathy in children and youth: New and emerging risk factors
Akıncı, G., Savelieff, M. G., Gallagher, G., Callaghan, B. C., & Feldman, E. L. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13153 · Cited by 33
Self-citationA Role for Fatty Acids in Peripheral Neuropathy Associated with Type 2 Diabetes and Prediabetes
Rumora, A. E., Kim, B., & Feldman, E. L. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0155 · Cited by 32
“This study examined incident PN in T2D subjects at a 13-year follow-up appointment after enrollment in the ADDITION-Denmark study (6).”
Self-citationDiabetes and Parkinson’s Disease: Understanding Shared Molecular Mechanisms
König, A., & Outeiro, T. F. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230104 · Cited by 32
Zhou, R., Li, F., Chen, G., Fu, Q. J., Gu, S., & Wu, X. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13075 · Cited by 34
“Overall, psychosocial stress appears to have a greater impact on women than on men.48 However, limited studies have evaluated the sex-specific difference in the relation between WC and the development of DN.49 Further research is required to elucidate the complex pathophysiology underlying sex differences between abdo…”
BackgroundInfluentialDiabetic neuropathy: Past, present, and future.
Aldave, J. E. Q., Durand‐Vásquez, M. D. C., Osorio, E. R. G., Suárez-Rojas, J., Roseboom, P. J., Alcalá‐Mendoza, R. M., Arroyo, J., Zavaleta‐Gutiérrez, F. E., Urteaga, L. A. C., & Concepción‐Zavaleta, M. J. (2023) · PubMed Central · doi:10.22088/cjim.14.2.153 · Cited by 47
Interaction between magnesium and methylglyoxal in diabetic polyneuropathy and neuronal models
Strom, A., Straßburger, K., Schmuck, M. R., Shevalye, H., Davidson, E. P., Zivehe, F., Bönhof, G. J., Reimer, R., Belgardt, B., Fleming, T. H., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101114 · Cited by 26
“The ADDITION-Denmark study identified higher methylglyoxal levels as a risk factor for incident DSPN [41].”
BackgroundSelf-citationAdvances in diet-induced rodent models of metabolically acquired peripheral neuropathy
Eid, S., & Feldman, E. L. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.049337 · Cited by 27
“Our laboratory ’ s clinical findings demonstrate that obesity and prediabetes are major PN drivers (Andersen et al., 2018; Callaghan et al., 2018, 2020, 2016b).”
Self-citationBönhof, G. J., Herder, C., & Ziegler, D. (2021) · Current Diabetes Reviews · doi:10.2174/1573399817666210412123740 · Cited by 29
Glucagon Prevents Cytotoxicity Induced by Methylglyoxal in a Rat Neuronal Cell Line Model
Mohiuddin, M. S., Himeno, T., Yamada, Y., Morishita, Y., Kondo, M., Tsunekawa, S., Kato, Y., Nakamura, J., & Kamiya, H. (2021) · Biomolecules · doi:10.3390/biom11020287 · Cited by 23
“Accumulating evidence has suggested that a high MG level is the key factor for developing DPN [38].”
Issues and challenges in diabetic neuropathy management: A narrative review
Ismail, C. A. N. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i6.741 · Cited by 31
Al-Saoudi, E., Christensen, M. M. B., Nawroth, P. P., Fleming, T. H., Hommel, E. E., Jørgensen, M. E., Fleischer, J., & Hansen, C. S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.891442 · Cited by 28
Self-citationHistory of lower-limb complications and risk of cancer death in people with type 2 diabetes
Mohammedi, K., Harrap, S. B., Mancia, G., Marre, M., Poulter, N. R., Chalmers, J. P., & Woodward, M. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01198-y · Cited by 25
Anson, M., Henney, A. E., Edwards, H., Ibarburu, G. H., Mordi, I. R., Jaffar, S. S., Garrib, A. V., Lip, G. Y. H., Wang, D., Nabrdalik, K., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112431 · Cited by 25
“It is well known that rates of neuropathy increase with length of duration of diabetes, a Danish longitudinal study reported a cumulative incidence of 10 % over a 13 year follow up period from initial diagnosis of T2D [37].”
Cuyubamba, O., Braga, C., Swift, D. D., Stickney, J. T., & Viel, C. (2025) · Cells · doi:10.3390/cells14070477 · Cited by 20
“While the risk factor with the strongest association for developing DPN is poor glycemic control [20–22], other independent risk factors like obesity, an increased waist-to-hip ratio, hypertension, dyslipidemia, hypertriglyceridemia and smoking are well-described [20,21,23–26].”
A Machine Learning-Based Severity Prediction Tool for the Michigan Neuropathy Screening Instrument
Haque, F., Reaz, M. B. I., Chowdhury, M. E. H., Shapiai, M. I., Malik, R. A., Alhatou, M. I., Kobashi, S., Ara, I., Ali, S. H. M., Bakar, A. A. A., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13020264 · Cited by 25
Tu, Z., Du, J., Ge, X., Peng, W., Shen, L., Xia, L., Jiang, X., Hu, F., & Huang, S. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01609-3 · Cited by 20
Lim, J. Z. M., Burgess, J., Ooi, C. G., Ponirakis, G., Malik, R. A., Wilding, J. P. H., & Alam, U. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02208-z · Cited by 19
“Obesity is associated with systemic inflammation and endothelial dysfunction which can lead to peripheral neuropathy in both type 2 diabetes (T2D) [5], and type 1 diabetes (T1D) [6].”
BackgroundInfluentialLiu, X., Chen, D., Fu, H., Liu, X., Zhang, Q.-M., Zhang, J., Ding, M., Wen, J., & Chang, B. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1128069 · Cited by 23
Kristensen, F., Christensen, D. H., Callaghan, B. C., Stidsen, J. V., Nielsen, J. S., Højlund, K., Beck‐Nielsen, H., Jensen, T. S., Andersen, H., Vestergaard, P., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0079 · Cited by 19
Self-citationNaqvi, S. S. Z. H., İmani, S., Hosseinifard, H., Wen, Q., Shahzad, M. N., Ijaz, I., Deng, Y., Guo, M., & Xu, Y. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-019-0453-5 · Cited by 20
Mizrak, H. I., Kufaishi, H., Hecquet, S. K., Hansen, T. W., Pop‐Busui, R., Rossing, P. R., Brock, B., & Hansen, C. S. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108761 · Cited by 18
Hushmandi, K., Einollahi, B., Aow, R., Suhairi, S. B., Klionsky, D. J., Aref, A. R., Reiter, R. J., Makvandi, P., Rabiee, N., Xu, Y., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107394 · Cited by 19
The Epidemiology of Diabetic Neuropathy
Hansen, C. S., Määttä, L. L., Andersen, S. T., & Charles, M. H. (2023) · Contemporary Diabetes · doi:10.1007/978-3-031-15613-7_2 · Cited by 17
Self-citation
Metadata
- Authors
- Andersen, S. T., Witte, D. R., Dalsgaard, E.-M., Andersen, H., Nawroth, P., Fleming, T., Jensen, T. M., Finnerup, N. B., Jensen, T. S., Lauritzen, T., Feldman, E. L., Callaghan, B. C., & Charles, M.
- Affiliations
- Aarhus University (DK)
- Aarhus University Hospital (DK)
- University Hospital Heidelberg (DE)
- University of Michigan (US)
- Corresponding author
- Andersen, Signe T.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-02-27
- Volume
- 41
- Issue
- 5
- Pages
- 1068-1075
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2790769408
- Cited by
- 248
- References
- 41
- Citations by year
- 2026: 16 · 2025: 38 · 2024: 36 · 2023: 38 · 2022: 28 · 2021: 37 · 2020: 29 · 2019: 17 · 2018: 9
- FWCI
- 15.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Site cant be reached (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Funders
- Novo Nordisk (Novo Nordisk Foundation Challenge Programme grant)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetic Foot Ulcer Assessment and Management
- Keywords
- diabetic polyneuropathy, type 2 diabetes, risk factors, Michigan Neuropathy Screening Instrument, methylglyoxal, HDL cholesterol, LDL cholesterol, waist circumference, body mass index, age, weight, diabetes screening, primary care, neuropathy prevention, intensive diabetes treatment, cumulative incidence, long-term follow-up
- MeSH terms
- Aged, Denmark, Diabetes Mellitus, Type 2, Diabetic Neuropathies, Female, Follow-Up Studies, Humans, Male, Mass Screening, Middle Aged, Obesity, Primary Health Care, Risk Factors, Cohort Studies, Incidence, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.